Entecavir is better than lamivudine in terms of a comprehensive assessment of current clinical data and treatment efficacy. In terms of drug resistance alone, the 1-year resistance rate of lamivudine is close to 20% and the 5-year resistance rate is more than 50%, while the 5-year resistance rate of entecavir is less than 1.6%. If you take lamivudine for a long time, the resistance rate will gradually increase, and many of the antiviral treatments for hepatitis B require a long course of treatment or even lifelong medication, especially for patients with cirrhosis, when the resistance appears, it will have cross-resistance to many other antiviral drugs, which brings great trouble to the treatment of hepatitis B. In particular, patients with cirrhosis often face the risk of failing to control the virus and progressing to liver failure after the emergence of drug resistance. The world’s major clinical guidelines now include entecavir as the first-line antiviral drug and no longer use lamivudine.